29 abril 2015
A new targeted therapy drug against EGFR-mutation driven lung tumors that have become resistant to current therapies shows activity against the most common resistance mutation, significantly improving outcomes for patients.
http://feeds.sciencedaily.com/~r/sciencedaily/~3/ORyFq901JNg/150429182434.htm
